Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 40 Issue 6, June 2022

Algae-encoded biopharmaceuticals

An illustration of spirulina powder, which can be engineered to produce therapeutic proteins for human consumption. The method, developed by Jester et al., overcomes limitations in current genetic tools to generate stable spirulina lines expressing high levels of bioactive proteins at large scale.

See Jester et al.

Image: Shutterstock. Cover Design: Erin Dewalt.

Volume 40 Issue 6

Editorial

  • Interest is growing in genome-editing tools that can insert large chunks of DNA into the genome — and avoid the double-strand breaks associated with CRISPR–Cas9 genotoxicity.

    Editorial

    Advertisement

Top of page ⤴

News

Top of page ⤴

Bioentrepreneur

Top of page ⤴

Correspondence

Top of page ⤴

Features

  • A survey of national R&D-driven health biotech sectors ranks Switzerland, Sweden and the United States as leading centers for R&D-driven biotech. John Hodgson and Deanna Schreiber-Gregory report.

    • John Hodgson
    • Deanna Schreiber-Gregory
    Feature
  • Patents

    • Even if Amarin prevails in its patent infringement lawsuit, its key patents on Vascepa are likely to be ruled invalid in ongoing litigation, opening the way for generic formulations.

      • Gregory Curfman
      • Justin Cole
      Patents
    • Recent patents relating to CRISPR methods and compositions for gene editing and therapeutic use.

      Patents
Top of page ⤴

News & Views

Top of page ⤴

Research Briefings

Top of page ⤴

Research

Top of page ⤴

Amendments & Corrections

Top of page ⤴

Careers & Recruitment

Top of page ⤴

Search

Quick links